Payment overview · 2025
General Payments
$405.51
19 reported records · 7 companies
Healthcare provider profile · identity verified
Leann M Byrd, MD
Allopathic & Osteopathic Physicians|Family Medicine · JEFFERSON CITY, TN · NPI 1104808906
Verified facts
What the public records show
CMS Open Payments records show Leann M Byrd, MD received $405.51 in general payments during 2025 across 19 reported records.
HEARTFLOW, INC. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $111.91 | 27.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.28 | 27.4% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $105.84 | 26.1% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.14 | 5.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.96 | 5.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.37 | 4.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.01 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.51 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $111.91 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.28 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $91.75 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.12 | 5 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 14 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 46 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
46 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 91 |
| Omeprazole | Omeprazole | 321 | 94 |
| Lisinopril | Lisinopril | 310 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 298 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 232 | 68 |
| Gabapentin | Gabapentin | 206 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 56 |
| Potassium Chloride | Potassium Chloride | 170 | 45 |
| Losartan Potassium | Losartan Potassium | 156 | 46 |
| Tramadol Hcl | Tramadol Hcl | 143 | 23 |
| Metformin Hcl Er | Metformin Hcl | 141 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 38 |
| Simvastatin | Simvastatin | 137 | 37 |
| Alendronate Sodium | Alendronate Sodium | 132 | 36 |
| Montelukast Sodium | Montelukast Sodium | 131 | 40 |
| Meloxicam | Meloxicam | 129 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 32 |
| Eliquis | Apixaban | 126 | 26 |
| Buspirone Hcl | Buspirone Hcl | 125 | 31 |
| Metformin Hcl | Metformin Hcl | 122 | 38 |
| Alprazolam | Alprazolam | 115 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | 28 |
| Trazodone Hcl | Trazodone Hcl | 110 | 30 |
| Furosemide | Furosemide | 109 | 38 |
| Prednisone | Prednisone | 104 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 25 |
| Sertraline Hcl | Sertraline Hcl | 90 | 28 |
| Lorazepam | Lorazepam | 86 | 18 |
| Xarelto | Rivaroxaban | 85 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 26 |
| Allopurinol | Allopurinol | 68 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 22 |
| Atenolol | Atenolol | 65 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 18 |
| Clonidine Hcl | Clonidine Hcl | 63 | 14 |
| Glimepiride | Glimepiride | 58 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 26 |
| Ozempic | Semaglutide | 56 | 12 |
| Carvedilol | Carvedilol | 52 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Valsartan | Valsartan | 48 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 17 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 34 |
| Famotidine | Famotidine | 43 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Estradiol | Estradiol | 42 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 41 | 41 |
| Mirtazapine | Mirtazapine | 41 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 11 |
| Fluconazole | Fluconazole | 37 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 22 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 11 |
| Azithromycin | Azithromycin | 35 | 27 |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 14 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 21 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 19 |
| Diazepam | Diazepam | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Nystatin | Nystatin | 23 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 19 |
| Glipizide | Glipizide | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 15 |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Cimetidine | Cimetidine | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $405.51 · 19 records | HEARTFLOW, INC. | AREXVY, Dexcom G6 Transmitter, ELIQUIS, ETERNA, FFRct, GVOKE HYPOPEN, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error